Lab notebook

What changed this month, on the floor.

Most supplement companies talk about innovation in press releases. We keep a notebook. Method changes, supplier swaps, rejected lots, and the occasional ingredient we pulled from the catalog, written down the day they happened.

  1. Rejected lot, J. Kim

    Magnesium glycinate lot MG-2604-A returned to supplier

    Heavy-metals panel came back with arsenic at 0.18 ppm, under the federal limit, over our internal X-list ceiling of 0.10 ppm. Three pallets returned to the supplier and a replacement lot is in incoming QC. No customer product was filled from this lot.

  2. Ingredient, P. Anand

    Added: PQQ (pyrroloquinoline quinone disodium salt)

    After eight months on the watch list, PQQ clears our evidence threshold for mitochondrial biogenesis support. Available in the builder at 5, 10, and 20 mg. Sourced from a single Tokyo supplier with USP-grade COAs on every lot.

  3. Method, M. Ellsworth

    Switched dissolution testing to USP <711> Apparatus 2 (paddle)

    Our previous Apparatus 1 (basket) setup was giving inconsistent results on larger capsules. Apparatus 2 with sinkers is the modern default for solid orals and gives us cleaner data. All capsule formulas re-validated under the new method.

  4. Supplier, J. Kim

    Vitamin D3 source consolidated to one Norwegian lanolin supplier

    We had three vetted suppliers. One was bought by a private-equity rollup last quarter and we don't yet trust the new ownership's QC. Volume is now split between the remaining two, with the Norwegian source as primary for traceability.

  5. Equipment, J. Kim

    Second analytical balance commissioned (Mettler XPR205)

    Throughput on the fill line was bottlenecked by single-balance check-weighing. The XPR205 reads to 0.01 mg and is now paired with the existing unit on a calibrated rotation. Daily verification against NIST-traceable weights remains unchanged.

  6. Ingredient, M. Ellsworth

    Removed: Phenibut (all forms)

    FDA issued a warning letter to a competing manufacturer using phenibut in dietary supplements. We had it on the X-list already, but pulled the data sheet entirely so it cannot be requested through the physician portal.

  7. People, M. Ellsworth

    Welcome Dr. Lila Park, PharmD, to the review rotation

    Lila joins from a Part 503A compounding pharmacy in Seattle. She'll cover the Tuesday and Thursday review windows. Four pharmacists now rotate through formulation review.

  8. Method, P. Anand

    Stability testing extended to 18 months at 25 °C / 60% RH

    Most of our formulations carry a 12-month BUD (beyond-use date) because that's all we had data for. The 18-month pull-points are now in, and ingredients in dry capsule form will be relabeled to 18 months as their data clears.

Older entries are kept in our batch records and available on request to physicians, regulators, and reporters.

clinical@vitamet.com